JP2019531697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531697A5 JP2019531697A5 JP2018567883A JP2018567883A JP2019531697A5 JP 2019531697 A5 JP2019531697 A5 JP 2019531697A5 JP 2018567883 A JP2018567883 A JP 2018567883A JP 2018567883 A JP2018567883 A JP 2018567883A JP 2019531697 A5 JP2019531697 A5 JP 2019531697A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- sialidase
- surface molecule
- cell surface
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 16
- 108010006232 Neuraminidase Proteins 0.000 claims 11
- 102000005348 Neuraminidase Human genes 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 claims 1
- 101001123851 Homo sapiens Sialidase-2 Proteins 0.000 claims 1
- 101001123847 Homo sapiens Sialidase-3 Proteins 0.000 claims 1
- 101000601384 Homo sapiens Sialidase-4 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 101900324552 Salmonella typhimurium Sialidase Proteins 0.000 claims 1
- 102100028760 Sialidase-1 Human genes 0.000 claims 1
- 102100028755 Sialidase-2 Human genes 0.000 claims 1
- 102100028756 Sialidase-3 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 241000607626 Vibrio cholerae Species 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 102000047925 human NEU4 Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940118696 vibrio cholerae Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022131521A JP7496629B2 (ja) | 2016-07-01 | 2022-08-22 | 標的化された細胞表面編集のための複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357645P | 2016-07-01 | 2016-07-01 | |
| US62/357,645 | 2016-07-01 | ||
| PCT/US2017/040411 WO2018006034A1 (en) | 2016-07-01 | 2017-06-30 | Conjugates for targeted cell surface editing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022131521A Division JP7496629B2 (ja) | 2016-07-01 | 2022-08-22 | 標的化された細胞表面編集のための複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531697A JP2019531697A (ja) | 2019-11-07 |
| JP2019531697A5 true JP2019531697A5 (enExample) | 2020-08-06 |
| JP7187024B2 JP7187024B2 (ja) | 2022-12-12 |
Family
ID=60787043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567883A Active JP7187024B2 (ja) | 2016-07-01 | 2017-06-30 | 標的化された細胞表面編集のための複合体 |
| JP2022131521A Active JP7496629B2 (ja) | 2016-07-01 | 2022-08-22 | 標的化された細胞表面編集のための複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022131521A Active JP7496629B2 (ja) | 2016-07-01 | 2022-08-22 | 標的化された細胞表面編集のための複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11459398B2 (enExample) |
| EP (2) | EP3478314B1 (enExample) |
| JP (2) | JP7187024B2 (enExample) |
| KR (2) | KR102822525B1 (enExample) |
| CN (1) | CN109641038A (enExample) |
| AU (2) | AU2017290554B2 (enExample) |
| BR (1) | BR112018077362A2 (enExample) |
| CA (1) | CA3027234A1 (enExample) |
| DK (1) | DK3478314T5 (enExample) |
| ES (1) | ES2947312T3 (enExample) |
| IL (2) | IL263617B2 (enExample) |
| MX (1) | MX2018016393A (enExample) |
| SG (1) | SG11201811719RA (enExample) |
| WO (1) | WO2018006034A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3341411B1 (en) | 2015-08-28 | 2025-06-11 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
| GB201616006D0 (en) * | 2016-09-20 | 2016-11-02 | Univ Court Of The Univ Of St Andrews The | Cell modulation |
| WO2018231661A1 (en) * | 2017-06-12 | 2018-12-20 | Tianxin Wang | Methods and reagents to treat tumor and cancer |
| JP7462560B2 (ja) | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| AU2019282825A1 (en) * | 2018-06-07 | 2020-12-10 | Palleon Pharmaceuticals Inc. | Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder |
| AU2019282778A1 (en) | 2018-06-08 | 2020-12-10 | Alector Llc | Anti-Siglec-7 antibodies and methods of use thereof |
| GB201811291D0 (en) * | 2018-07-10 | 2018-08-29 | Univ Dublin City | A method of predicting response to treatment in cancer patients |
| EP3604551A1 (en) * | 2018-07-31 | 2020-02-05 | Université de Bretagne Occidentale | Complement-dependent cytotoxicity and sialylation as biomarkers for predicting clinical response to cancer treatment with antibody or derivative mediating complement activation |
| GB201819920D0 (en) * | 2018-12-06 | 2019-01-23 | Pneumagen Ltd | Cancer treatment |
| US20250049846A1 (en) * | 2019-01-03 | 2025-02-13 | Palleon Pharmaceuticals Inc. | Methods and compositions for treating cancer with immune cells |
| WO2020172072A1 (en) * | 2019-02-21 | 2020-08-27 | The General Hospital Corporation | Glycoengineering immunoglobulin e |
| AU2020299543A1 (en) * | 2019-07-03 | 2022-02-03 | Palleon Pharmaceuticals Inc. | Sialidase-HER2-antibody fusion proteins and methods of use thereof |
| AU2020301037A1 (en) * | 2019-07-03 | 2022-02-03 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| CA3145772A1 (en) * | 2019-07-03 | 2021-01-07 | Palleon Pharmaceuticals Inc. | Recombinant sialidases and methods of using the same |
| AU2020298628A1 (en) * | 2019-07-03 | 2022-02-03 | Palleon Pharmaceuticals Inc. | Sialidase-CD20-antibody fusion proteins and methods of use thereof |
| AU2020299614A1 (en) * | 2019-07-03 | 2022-02-03 | Palleon Pharmaceuticals Inc. | Sialidase-PD-L1-antibody fusion proteins and methods of use thereof |
| CA3174467A1 (en) * | 2020-05-13 | 2021-11-18 | Chad PECOT | Nucleic acid ligand conjugates and use thereof for delivery to cells |
| CA3191901A1 (en) * | 2020-07-21 | 2022-01-27 | The Scripps Research Institute | Disruption of cd28-sialoside ligand complexes to enhance t cell activation |
| US20240100177A1 (en) * | 2020-12-04 | 2024-03-28 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
| EP4314050A4 (en) * | 2021-04-02 | 2025-02-26 | The Board of Trustees of the Leland Stanford Junior University | BISPECIFIC MOLECULES AND RELATED COMPOSITIONS AND METHODS |
| EP4326334A1 (en) | 2021-04-23 | 2024-02-28 | GanNA Bio, Inc. | Glycan modified nucleic acids, methods of preparation, and therapeutic uses |
| WO2023129822A2 (en) * | 2021-12-28 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified bacterial peptidoglycan compositions and uses thereof |
| KR20250004918A (ko) * | 2022-05-04 | 2025-01-08 | 더 스크립스 리서치 인스티튜트 | 시알리다제 (sialidase) 융합 분자들 및 관련 용법들 |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2620649C3 (de) | 1976-05-11 | 1980-11-06 | Behringwerke Ag, 3550 Marburg | Immunologisches Adjuvans |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| FR2828386B1 (fr) | 2001-08-10 | 2004-06-11 | Jean Noel Acquaviva | Ecran de vision coupe-vent |
| CN1729013B (zh) | 2002-11-22 | 2012-10-03 | 耐百生物制药有限公司 | 广谱抗病毒化合物、药物制剂及其用途 |
| US8512710B2 (en) | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
| US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| EP1981483A1 (en) | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| CN101437536A (zh) * | 2006-03-23 | 2009-05-20 | 诺华有限公司 | 抗肿瘤细胞抗原抗体治疗 |
| EP1938835A1 (en) | 2006-12-29 | 2008-07-02 | Pevion Biotech AG | Non-specific immunostimulating agents |
| JP2013510169A (ja) | 2009-11-06 | 2013-03-21 | ネクスバイオ，インク． | 呼吸器管の治療及び予防のための方法、化合物、及び組成物 |
| AU2013274078A1 (en) * | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
| CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| UA105278C2 (ru) * | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| US10351828B2 (en) | 2013-03-15 | 2019-07-16 | Ansun Biopharma, Inc. | Method of protein purification from E. coli |
| US20160120961A1 (en) | 2013-06-10 | 2016-05-05 | Ansun Biopharma, Inc. | Treatment of merkel cell polyomavirus infection |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| US20160229882A1 (en) | 2013-09-17 | 2016-08-11 | The Regents Of The University Of California | Non-enzymatic, salt-mediated synthesis of polynucleic acids |
| US20170165334A1 (en) | 2015-12-11 | 2017-06-15 | Tianxin Wang | Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification |
| US20170119859A1 (en) | 2014-05-30 | 2017-05-04 | Ansun Biopharma, Inc. | Treatment of middle east respiratory syndrome coronavirus |
| JP2017532025A (ja) * | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 交差反応性ｓｉｇｌｅｃ抗体 |
| WO2016044656A1 (en) | 2014-09-17 | 2016-03-24 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus d68 |
| US20180177852A1 (en) | 2015-06-08 | 2018-06-28 | Ansun Biopharma, Inc. | Treatment of human metapneumovirus |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| US20180271997A1 (en) | 2016-05-31 | 2018-09-27 | Tianxin Wang | Methods and Reagents to Treat Tumor and Cancer |
| GB201616006D0 (en) | 2016-09-20 | 2016-11-02 | Univ Court Of The Univ Of St Andrews The | Cell modulation |
| US10940185B2 (en) | 2016-12-28 | 2021-03-09 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| WO2018231661A1 (en) | 2017-06-12 | 2018-12-20 | Tianxin Wang | Methods and reagents to treat tumor and cancer |
| US20220370527A1 (en) | 2018-07-20 | 2022-11-24 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
-
2017
- 2017-06-30 ES ES17821402T patent/ES2947312T3/es active Active
- 2017-06-30 MX MX2018016393A patent/MX2018016393A/es unknown
- 2017-06-30 SG SG11201811719RA patent/SG11201811719RA/en unknown
- 2017-06-30 DK DK17821402.9T patent/DK3478314T5/da active
- 2017-06-30 CA CA3027234A patent/CA3027234A1/en active Pending
- 2017-06-30 IL IL263617A patent/IL263617B2/en unknown
- 2017-06-30 JP JP2018567883A patent/JP7187024B2/ja active Active
- 2017-06-30 AU AU2017290554A patent/AU2017290554B2/en active Active
- 2017-06-30 KR KR1020237031968A patent/KR102822525B1/ko active Active
- 2017-06-30 EP EP17821402.9A patent/EP3478314B1/en active Active
- 2017-06-30 IL IL305907A patent/IL305907A/en unknown
- 2017-06-30 CN CN201780040962.1A patent/CN109641038A/zh active Pending
- 2017-06-30 US US16/308,732 patent/US11459398B2/en active Active
- 2017-06-30 BR BR112018077362-0A patent/BR112018077362A2/pt not_active Application Discontinuation
- 2017-06-30 EP EP23155976.6A patent/EP4218802A3/en active Pending
- 2017-06-30 KR KR1020197002051A patent/KR102581747B1/ko active Active
- 2017-06-30 WO PCT/US2017/040411 patent/WO2018006034A1/en not_active Ceased
-
2020
- 2020-12-15 AU AU2020289739A patent/AU2020289739B2/en active Active
-
2022
- 2022-08-22 JP JP2022131521A patent/JP7496629B2/ja active Active
- 2022-08-26 US US17/822,638 patent/US12404342B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| Hudson et al. | High avidity scFv multimers; diabodies and triabodies | |
| JP2020531043A5 (enExample) | ||
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020063262A5 (enExample) | ||
| Maleki et al. | Future prospects of monoclonal antibodies as magic bullets in immunotherapy | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2021502810A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| JP2019533475A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2017531427A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2011505146A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2014166186A5 (enExample) | ||
| JP2021512151A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2021512604A5 (enExample) | ||
| FI3806895T3 (fi) | Kasvainkudosta sitovia vasta-aineita ja niiden diagnostisia ja terapeuttisia käyttöjä | |
| Yang et al. | A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 |